Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been given an average recommendation of “Moderate Buy” by the thirteen analysts that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $39.50.

GMAB has been the topic of a number of analyst reports. Weiss Ratings upgraded Genmab A/S from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. New Street Research set a $43.00 target price on shares of Genmab A/S in a research note on Wednesday, July 22nd. Truist Financial assumed coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Finally, BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd.

Institutional Trading of Genmab A/S

Several hedge funds have recently modified their holdings of GMAB. Assetmark Inc. lifted its position in Genmab A/S by 2,423.8% during the 4th quarter. Assetmark Inc. now owns 233,852 shares of the company’s stock worth $7,203,000 after buying an additional 224,586 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in Genmab A/S by 15.5% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 364,756 shares of the company’s stock valued at $11,234,000 after acquiring an additional 48,894 shares in the last quarter. Pictet Asset Management Holding SA acquired a new stake in Genmab A/S in the 4th quarter valued at about $33,835,000. Kestra Private Wealth Services LLC bought a new position in shares of Genmab A/S in the fourth quarter worth about $833,000. Finally, SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Genmab A/S in the fourth quarter worth about $673,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Up 0.4%

NASDAQ GMAB opened at $32.96 on Wednesday. Genmab A/S has a 1-year low of $23.62 and a 1-year high of $35.43. The company has a market capitalization of $20.55 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 1.90 and a beta of 0.83. The stock’s 50 day moving average is $28.30 and its two-hundred day moving average is $27.91. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. Equities analysts forecast that Genmab A/S will post 1.17 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.